Efficacy of Heparinoid Cream Containing Pseudo-Ceramide for Remission of Atopic Dermatitis

• Published in: Clinical, cosmetic and investigational dermatology Vol. 14; pp. 1839 - 1847
• Main Authors: Matsuoka, Megumi, Okoshi, Keita, Ito, Shotaro, Kume, Takuji, Seki, Tsuyoshi, Nishizaka, Takahiro, Okada, Joji, Nagasawa, Azumi, Iijima, Makoto, Abe, Masatoshi, Nemoto, Osamu
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01-01-2021; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Advertising executives; Alcohol; Allergens; Atopic dermatitis; barrier; ceramide; Cytokines; Dermatitis; Eczema; Evaluation; heparinoid; Inflammation; lamellar; Lipids; Original Research; Permeability; Polyethylene terephthalate; Proteases; Remission (Medicine); Skin; skin hydration; Soap and cleaning agents industry; Steroids; transepidermal water loss; X-rays; Japan; Austria; ceramide; barrier; lamellar; transepidermal water loss; skin hydration; heparinoid; atopic dermatitis
• ISSN: 1178-7015; 1178-7015
• DOI: 10.2147/CCID.S337930

Atopic dermatitis (AD) is characterized by chronic inflammation, which frequently recurs, is exacerbated, and enters remission. A maintenance remission period is important for AD patients. We developed a formulation for use during AD remission, containing heparinoid and pseudo-ceramide that forms a lamellar structure. We evaluated the allergen permeability and examined the formulation's efficacy in maintaining remission in patients with AD.
Seventeen AD patients applied a cream containing 0.3% heparinoid and pseudo-ceramide (test cream group, n = 10), or a general cream containing 0.3% heparinoid (control cream group, n = 7) to their arm for four weeks after inducing remission with the application of a steroid cream for two weeks.
The lamellar structure of the test cream was confirmed with small- and wide-angle x-ray scattering analysis and observation by transmission electron microscopy. The test cream inhibited the penetration of V8 protease significantly compared to the control cream in vitro. According to AD severity score by dermatologists, the effects remission maintenance of the test cream group were comparable to those of the control cream group. However, the test cream group had a significantly increased skin hydration value compared to the control cream group. A significant decrease in transepidermal water loss, an indicator of skin barrier function, was shown in the test cream group compared to the control cream group.
The cream with lamellar structures containing heparinoid and pseudo-ceramides may inhibit allergen penetration. Moreover, skin properties improved during the remission period; thus, the formulation we developed was suitable for use during the AD remission period.